Clinical Trial Update: An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease [Phase 3]

View source ↗

Summary

An extension Phase 3 study of TAK-664 in Japanese patients with primary immunodeficiency disease has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• TAK-664

Snippet

Sponsor: Takeda | Conditions: Primary Immunodeficiency Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-01-20